{"id":"integrase-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Elevated creatinine kinase"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HIV integrase is an enzyme that catalyzes the integration of viral DNA into the human genome, a critical step in HIV replication. By inhibiting this enzyme, integrase inhibitors prevent viral DNA from becoming incorporated into host chromosomes, thereby blocking productive infection and viral replication. This class is used as part of combination antiretroviral therapy for HIV-1 infection.","oneSentence":"Integrase inhibitors block HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:24.576Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT07053384","phase":"PHASE1","title":"A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-07-10","conditions":"HIV Infections","enrollment":107},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT05986084","phase":"PHASE4","title":"Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-11-30","conditions":"Pre-Exposure Prophylaxis (PrEP), Breast Feeding","enrollment":500},{"nctId":"NCT04337450","phase":"PHASE2, PHASE3","title":"DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-04-22","conditions":"HIV Infections","enrollment":386},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT04820933","phase":"EARLY_PHASE1","title":"Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-01","conditions":"HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders","enrollment":26},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT05330923","phase":"","title":"Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-05-01","conditions":"Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fibrosis","enrollment":200},{"nctId":"NCT03483584","phase":"","title":"Incidence of HANA Conditions in HIV-infected Individuals","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2018-04-06","conditions":"HIV, Metabolic Syndrome, Osteopenia","enrollment":215},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT01737047","phase":"","title":"The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-04-01","conditions":"HIV Positive, Ageing","enrollment":1377},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306},{"nctId":"NCT06474364","phase":"PHASE4","title":"HIV Prevention and Care Interventions for Youth in Uganda","status":"RECRUITING","sponsor":"MU-JHU CARE","startDate":"2024-08-05","conditions":"HIV","enrollment":600},{"nctId":"NCT04665375","phase":"PHASE4","title":"Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2021-04-26","conditions":"Hiv, Weight Gain","enrollment":4},{"nctId":"NCT04636437","phase":"PHASE4","title":"Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2021-07-27","conditions":"HIV Infections","enrollment":147},{"nctId":"NCT07031063","phase":"PHASE4","title":"Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-04-01","conditions":"HIV Infection, Metabolic Syndrome, Antiretroviral Treatment","enrollment":124},{"nctId":"NCT06640192","phase":"PHASE2","title":"Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir","status":"RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2025-05-30","conditions":"HIV-1-infection","enrollment":24},{"nctId":"NCT05527418","phase":"PHASE2","title":"Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection","status":"RECRUITING","sponsor":"Eva Bonfill","startDate":"2024-01-26","conditions":"Recent HIV-1 Infection","enrollment":24},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT04019873","phase":"","title":"'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-18","conditions":"HIV Infections","enrollment":774},{"nctId":"NCT06704204","phase":"","title":"Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community","status":"NOT_YET_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2025-02","conditions":"HIV","enrollment":20},{"nctId":"NCT05300035","phase":"PHASE2","title":"Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-11","conditions":"HIV/AIDS and Infections","enrollment":69},{"nctId":"NCT01302847","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-04-20","conditions":"HIV Infections","enrollment":181},{"nctId":"NCT06706986","phase":"","title":"A Global Registry on Second GEneration and Long-acting InTegrase InhibiTor FAilures","status":"ENROLLING_BY_INVITATION","sponsor":"UMC Utrecht","startDate":"2023-09-01","conditions":"HIV, Therapy Failure","enrollment":250},{"nctId":"NCT05330143","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-06-28","conditions":"HIV-1-infection, HIV Infections, PD-L1 Gene Mutation","enrollment":19},{"nctId":"NCT02691065","phase":"PHASE4","title":"Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2017-01-20","conditions":"HIV","enrollment":6},{"nctId":"NCT06661317","phase":"","title":"Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens.","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2024-11-01","conditions":"HIV-1-infection, DRM, DRM Gene Mutation","enrollment":200},{"nctId":"NCT04688034","phase":"PHASE1","title":"Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.","status":"COMPLETED","sponsor":"Kiminori Kimura, MD","startDate":"2021-03-15","conditions":"Liver Cirrhosis","enrollment":5},{"nctId":"NCT06612554","phase":"NA","title":"Zn Supplementation in HIV Immunological Non Responders","status":"NOT_YET_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2025-01-02","conditions":"HIV, Zinc Status, HIV Infection","enrollment":120},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT04240210","phase":"PHASE4","title":"Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)","status":"TERMINATED","sponsor":"Midland Research Group, Inc.","startDate":"2019-09-17","conditions":"Human Immunodeficiency Virus","enrollment":1},{"nctId":"NCT02429791","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-14","conditions":"HIV Infections","enrollment":510},{"nctId":"NCT02422797","phase":"PHASE3","title":"Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-04-21","conditions":"HIV Infections","enrollment":518},{"nctId":"NCT06485154","phase":"PHASE4","title":"Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2024-06-01","conditions":"HIV Prevention","enrollment":100},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT01480713","phase":"PHASE3","title":"Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors","status":"COMPLETED","sponsor":"IrsiCaixa","startDate":"2012-05","conditions":"HIV-1 Infection","enrollment":41},{"nctId":"NCT02699736","phase":"","title":"EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV","status":"ENROLLING_BY_INVITATION","sponsor":"Rigshospitalet, Denmark","startDate":"1994-01","conditions":"HIV, Hepatitis B, Hepatitis C","enrollment":23000},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT02437110","phase":"PHASE1","title":"HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2019-04-01","conditions":"Amyotrophic Lateral Sclerosis","enrollment":122},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT04892654","phase":"PHASE3","title":"Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch","status":"RECRUITING","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-08-17","conditions":"HIV-1-infection","enrollment":150},{"nctId":"NCT04066036","phase":"","title":"Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-05-14","conditions":"HIV-1-infection","enrollment":1000},{"nctId":"NCT04675255","phase":"NA","title":"Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-01-01","conditions":"HIV I Infection, Adiposity","enrollment":8},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT01867320","phase":"EARLY_PHASE1","title":"Raltegravir for HAM/TSP","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2013-09-05","conditions":"HTLV-I Infection","enrollment":19},{"nctId":"NCT02227238","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-11","conditions":"HIV Infections","enrollment":627},{"nctId":"NCT04319718","phase":"PHASE1","title":"Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048","status":"COMPLETED","sponsor":"Hillier, Sharon, PhD","startDate":"2020-08-19","conditions":"Pharmacokinetics, Safety","enrollment":37},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT02075593","phase":"PHASE3","title":"ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-17","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections, Arthralgia","enrollment":4},{"nctId":"NCT03782142","phase":"","title":"Effect on HIV Medications on EPC Cells","status":"COMPLETED","sponsor":"Sabyasachi Sen","startDate":"2018-11-01","conditions":"AIDS","enrollment":22},{"nctId":"NCT01231516","phase":"PHASE3","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-26","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":724},{"nctId":"NCT04302896","phase":"EARLY_PHASE1","title":"Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs","status":"COMPLETED","sponsor":"Rhonda Brand","startDate":"2020-08-31","conditions":"Medication Adherence, HIV","enrollment":30},{"nctId":"NCT04229290","phase":"PHASE4","title":"Second-line Switch to Dolutegravir Study","status":"COMPLETED","sponsor":"University of Nairobi","startDate":"2020-02-12","conditions":"HIV-1-infection","enrollment":795},{"nctId":"NCT00515827","phase":"PHASE2","title":"Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-11","conditions":"HIV Infections","enrollment":53},{"nctId":"NCT00660972","phase":"PHASE1","title":"Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00852618","phase":"","title":"Intensive Viral Dynamics Substudy of A5248","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Treatment Naive","enrollment":11},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT01896921","phase":"PHASE3","title":"Switch to Maraviroc + Integrase Inhibitor","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2013-09","conditions":"HIV","enrollment":7},{"nctId":"NCT02178800","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-02","conditions":"HIV Infections","enrollment":199},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT04051970","phase":"PHASE3","title":"Reducing Antiretroviral Treatments","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2019-11-27","conditions":"HIV-1-infection","enrollment":360},{"nctId":"NCT02611895","phase":"NA","title":"Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-03","conditions":"HIV-1 Infection","enrollment":120},{"nctId":"NCT03422172","phase":"PHASE1","title":"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-04-10","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT02383108","phase":"PHASE2, PHASE3","title":"Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-06","conditions":"HIV Infection","enrollment":318},{"nctId":"NCT02178592","phase":"PHASE3","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-01-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":113},{"nctId":"NCT01288417","phase":"PHASE1","title":"Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2011-08","conditions":"HIV Infections, HCV Infections","enrollment":24},{"nctId":"NCT02478632","phase":"PHASE3","title":"Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-06-12","conditions":"HIV Infections","enrollment":102},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT03542786","phase":"NA","title":"Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic","status":"COMPLETED","sponsor":"AB Biotics, SA","startDate":"2017-12-18","conditions":"HIV, Premature Aging","enrollment":89},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT03964584","phase":"","title":"Evaluation of the Neurological and Psychiatric Adverse Events of Dolutegravir and Bictegravir in Real Life","status":"WITHDRAWN","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2019-09-01","conditions":"HIV+ Patients","enrollment":""},{"nctId":"NCT03327740","phase":"","title":"PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-09-30","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":1},{"nctId":"NCT03336346","phase":"","title":"Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana","status":"COMPLETED","sponsor":"Columbia University","startDate":"2017-11-15","conditions":"Contraceptive Usage, HIV Infections, Drug Interaction","enrollment":148},{"nctId":"NCT01378910","phase":"PHASE4","title":"Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2011-06","conditions":"HIV","enrollment":74},{"nctId":"NCT01231529","phase":"PHASE1","title":"GSK1349572 Hepatic Impairment Study","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-11-19","conditions":"Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT03314064","phase":"PHASE4","title":"Phase 4 Study of Dolutegravir (DTG) in Russian Federation","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-12-08","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":43},{"nctId":"NCT03280940","phase":"","title":"Impact of Different Integrase Inhibitor Based Regimen on Immune Activation Among HIV naïve Patient (INTATTI)","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2017-09-01","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT03708289","phase":"","title":"Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals","status":"TERMINATED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-09","conditions":"HIV-1, Treatment-naïve","enrollment":120},{"nctId":"NCT02551523","phase":"PHASE2","title":"Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2016-11","conditions":"Monotherapy, Dolutegravir, Primary HIV Infection","enrollment":101},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT01568892","phase":"PHASE3","title":"Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-04-18","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00904644","phase":"","title":"Raltegravir in the Swiss HIV Cohort Study","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2008-04","conditions":"HIV Infection","enrollment":200},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT00951015","phase":"PHASE2","title":"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-07-30","conditions":"Infection, Human Immunodeficiency Virus","enrollment":208},{"nctId":"NCT02076178","phase":"PHASE2","title":"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-03-27","conditions":"Infection, Human Immunodeficiency Virus","enrollment":127},{"nctId":"NCT00920426","phase":"PHASE2","title":"Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-06-09","conditions":"Infection, Human Immunodeficiency Virus","enrollment":9},{"nctId":"NCT02572947","phase":"PHASE2","title":"A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients","status":"COMPLETED","sponsor":"Calmy Alexandra","startDate":"2016-06","conditions":"Human Immunodeficiency Virus, Dolutegravir, Monotherapy","enrollment":8},{"nctId":"NCT03199690","phase":"PHASE1","title":"A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers","status":"UNKNOWN","sponsor":"St. Stephens Clinical Research","startDate":"2017-10","conditions":"HIV-1-infection, Tuberculosis","enrollment":16},{"nctId":"NCT01098526","phase":"PHASE1","title":"GSK1349572 Drug Interaction Study With Efavirenz","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-03-16","conditions":"Infections, Human Immunodeficiency Virus and Herpesviridae","enrollment":12},{"nctId":"NCT00641641","phase":"NA","title":"The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2008-03","conditions":"HIV Infection","enrollment":16}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"AMYLASE INCREASED"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"INSOMNIA"},{"count":1,"reaction":"IRIDOCYCLITIS"},{"count":1,"reaction":"KAPOSI'S SARCOMA"},{"count":1,"reaction":"MALABSORPTION"},{"count":1,"reaction":"MESENTERIC VEIN THROMBOSIS"},{"count":1,"reaction":"MYCOBACTERIUM AVIUM COMPLEX INFECTION"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":1284,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Integrase Inhibitor","genericName":"Integrase Inhibitor","companyName":"McGill University Health Centre/Research Institute of the McGill University Health Centre","companyId":"mcgill-university-health-centre-research-institute-of-the-mcgill-university-heal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Integrase inhibitors block HIV integrase, preventing the virus from inserting its genetic material into the host cell's DNA. Used for HIV-1 infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}